Botulinum toxin treatments of neurological and neuropsychiatric disorders

Details for Australian Patent Application No. 2004316860 (hide)

Owner Allergan, Inc.

Inventors Blumenfeld, Andrew M.

Agent Davies Collison Cave

Pub. Number AU-B-2004316860

PCT Pub. Number WO2005/084705

Priority 60/515,362 29.10.03 US; 60/556,150 24.03.04 US; 60/574,957 26.05.04 US

Filing date 26 October 2004

Wipo publication date 15 September 2005

Acceptance publication date 3 December 2009

International Classifications

A61K 39/08 (2006.01) Medicinal preparations containing antigens or antibodies - Clostridium, e.g. Clostridium tetani

Event Publications

18 May 2006 PCT application entered the National Phase

  PCT publication WO2005/084705 Priority application(s): WO2005/084705

3 December 2009 Application Accepted

  Published as AU-B-2004316860

1 April 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004316863-Selective reduction of cupriferous calcine

2004316845-Absorbent article with a reclosable side panel